Table I.
Health, meiotic maturation status and diameter of oocytes retrieved from antral follicles at Week 5 (34 h after the addition of hCG) in progestin (P, R5020) and estradiol (E2) replacement experiments.
| Number (n) of |
Oocyte diameter (µm) |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Follicles harvested | Oocytes retrieved | Degenerated oocytes (%) | Healthy oocytes |
GV | MI | MII | |||
| GV | MI | MII | |||||||
| P replacement | |||||||||
| Control | 22 | 22 | 9 (41 ± 10)a | 12 | 1 | 0 | 102 ± 1 | 108 | – |
| TRL | 8 | 8 | 5 (58 ± 8)b | 3 | 0 | 0 | 101 ± 4 | – | – |
| TRL + LP | 12 | 11 | 6 (47 ± 7)a,b | 5 | 0 | 0 | 99 ± 1 | – | – |
| TRL + HP | 5 | 5 | 4 (83 ± 17)b | 1 | 0 | 0 | 101 | – | – |
| E2 replacement | |||||||||
| Control | 13 | 12 | 5 (38 ± 7)A | 6 | 0 | 1 | 102 ± 2 | – | 115 |
| TRL | 9 | 9 | 7 (87 ± 13)B | 2 | 0 | 0 | 96 ± 1 | – | – |
| TRL + LE | 14 | 13 | 4 (28 ± 15)A | 7 | 1 | 1 | 100 ± 1 | 103 | 112 |
| TRL + HE | 9 | 9 | 3 (25 ± 14)A | 5 | 1 | 0 | 104 ± 3 | 107 | – |
CONT, control, TRL, trilostane, LP, low-dose P, HP, high-dose P, LE, low-dose E2 and HE, high-dose E2.
Different lower and capital case letters represent differences in P and E2 replacement experiments, respectively, between treatment groups.